
|Articles|February 15, 2003
- BioPharm International-02-01-2003
- Volume 16
- Issue 2
Becoming a Partner of Choice and Evaluating Prospective Alliances
Author(s)Jan Heybroek, David Wallis
by David Wallis, Dechert and Jan Heybroek Whether you're on the inlicensing or outlicensing side of a collaboration, attention must be paid to putting forth the right image and learning about your prospective partners before the alliance is struck.
Advertisement
Articles in this issue
over 22 years ago
Guest Editorial: Maybe You Need a Corporate Marriage Counselorover 22 years ago
Inside Washington: AIDS Prevention Campaign Spotlights Biotechover 22 years ago
Survival Strategies: Keeping Tabs on Trainingover 22 years ago
Outsourcing Outlook: Contract Services' Crystal BallNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
2
Everything to Know About Cell and Gene Therapy in 2025
3
Why Product-Specific Strategies Matter in Advanced Therapy Manufacturing (Part 3)
4
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
5